APO Research
Talk to an analyst

APO RESEARCH · REPORT

Neuropeptide Y Receptor Type 2

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Neuropeptide Y Receptor Type 2 Market Outlook and Growth Opportunities 2026

19 December 2025190 pages

Choose your research edition.

Industry ResearchNeuropeptide Y Receptor Type 2 Industry Research Report 2026108 pages · $2,950 USDIndustry Growth & TrendsGlobal Neuropeptide Y Receptor Type 2 Industry Growth and Trends Forecast to 203273 pages · $3,450 USDMarket StructureGlobal Neuropeptide Y Receptor Type 2 Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032170 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Neuropeptide Y Receptor Type 2 Market Outlook and Growth Opportunities 2026190 pages · $4,250 USDMarket Analysis & ForecastGlobal Neuropeptide Y Receptor Type 2 Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

The global Neuropeptide Y Receptor Type 2 market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Neuropeptide Y Receptor Type 2 is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Neuropeptide Y Receptor Type 2 is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Neuropeptide Y Receptor Type 2 is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Neuropeptide Y Receptor Type 2 market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Neuropeptide Y Receptor Type 2 market include Novo Nordisk A/S, XL-protein GmbH and Gila Therapeutics Inc, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Neuropeptide Y Receptor Type 2 market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Neuropeptide Y Receptor Type 2 and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Neuropeptide Y Receptor Type 2 sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Neuropeptide Y Receptor Type 2 market size, projected growth trends, production technologies, key applications, and end-use industries.

Neuropeptide Y Receptor Type 2 Segment by Company

Novo Nordisk A/S

XL-protein GmbH

Gila Therapeutics Inc

Neuropeptide Y Receptor Type 2 Segment by Type

GT-002

NN-9748

XL-310

Others

Neuropeptide Y Receptor Type 2 Segment by Application

Obesity

Epilepsy

Type 2 Diabetes

Others

Neuropeptide Y Receptor Type 2 Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Colombia

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Neuropeptide Y Receptor Type 2 status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Neuropeptide Y Receptor Type 2 market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Neuropeptide Y Receptor Type 2 significant trends, drivers, influence factors in global and regions.

6. To analyze Neuropeptide Y Receptor Type 2 competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Neuropeptide Y Receptor Type 2 market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Neuropeptide Y Receptor Type 2 and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Neuropeptide Y Receptor Type 2.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Neuropeptide Y Receptor Type 2 market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Neuropeptide Y Receptor Type 2 industry.

Chapter 3: Detailed analysis of Neuropeptide Y Receptor Type 2 manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Neuropeptide Y Receptor Type 2 in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Neuropeptide Y Receptor Type 2 in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Neuropeptide Y Receptor Type 2 Industry Trends Table 2. Neuropeptide Y Receptor Type 2 Industry Drivers Table 3. Neuropeptide Y Receptor Type 2 Industry Opportunities and Challenges Table 4. Neuropeptide Y Receptor Type 2 Industry Restraints Table 5. Global Neuropeptide Y Receptor Type 2 Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Neuropeptide Y Receptor Type 2 Revenue Share by Company (2021-2026) Table 7. Global Neuropeptide Y Receptor Type 2 Sales Volume by Company (W Units) & (2021-2026) Table 8. Global Neuropeptide Y Receptor Type 2 Sales Volume Share by Company (2021-2026) Table 9. Global Neuropeptide Y Receptor Type 2 Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Neuropeptide Y Receptor Type 2 Company Ranking, (2024-2026) & (USD Million) Table 11. Global Neuropeptide Y Receptor Type 2 Key Company Manufacturing Base & Headquarters Table 12. Global Neuropeptide Y Receptor Type 2 Company, Product Type & Application Table 13. Global Neuropeptide Y Receptor Type 2 Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Neuropeptide Y Receptor Type 2 by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of GT-002 Table 18. Significant Companies of NN-9748 Table 19. Significant Companies of XL-310 Table 20. Significant Companies of Others Table 21. Global Neuropeptide Y Receptor Type 2 Sales Volume by Type 2021 VS 2025 VS 2032 (W Units) Table 22. Global Neuropeptide Y Receptor Type 2 Sales Volume by Type (2021-2026) & (W Units) Table 23. Global Neuropeptide Y Receptor Type 2 Sales Volume by Type (2027-2032) & (W Units) Table 24. Global Neuropeptide Y Receptor Type 2 Sales Volume Share by Type (2021-2026) Table 25. Global Neuropeptide Y Receptor Type 2 Sales Volume Share by Type (2027-2032) Table 26. Global Neuropeptide Y Receptor Type 2 Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Neuropeptide Y Receptor Type 2 Sales Value by Type (2021-2026) & (US$ Million) Table 28. Global Neuropeptide Y Receptor Type 2 Sales Value by Type (2027-2032) & (US$ Million) Table 29. Global Neuropeptide Y Receptor Type 2 Sales Value Share by Type (2021-2026) Table 30. Global Neuropeptide Y Receptor Type 2 Sales Value Share by Type (2027-2032) Table 31. Significant Companies of Obesity Table 32. Significant Companies of Epilepsy Table 33. Significant Companies of Type 2 Diabetes Table 34. Significant Companies of Others Table 35. Global Neuropeptide Y Receptor Type 2 Sales Volume by Application 2021 VS 2025 VS 2032 (W Units) Table 36. Global Neuropeptide Y Receptor Type 2 Sales Volume by Application (2021-2026) & (W Units) Table 37. Global Neuropeptide Y Receptor Type 2 Sales Volume by Application (2027-2032) & (W Units) Table 38. Global Neuropeptide Y Receptor Type 2 Sales Volume Share by Application (2021-2026) Table 39. Global Neuropeptide Y Receptor Type 2 Sales Volume Share by Application (2027-2032) Table 40. Global Neuropeptide Y Receptor Type 2 Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 41. Global Neuropeptide Y Receptor Type 2 Sales Value by Application (2021-2026) & (US$ Million) Table 42. Global Neuropeptide Y Receptor Type 2 Sales Value by Application (2027-2032) & (US$ Million) Table 43. Global Neuropeptide Y Receptor Type 2 Sales Value Share by Application (2021-2026) Table 44. Global Neuropeptide Y Receptor Type 2 Sales Value Share by Application (2027-2032) Table 45. Global Neuropeptide Y Receptor Type 2 Sales by Region: 2021 VS 2025 VS 2032 (W Units) Table 46. Global Neuropeptide Y Receptor Type 2 Sales by Region (2021-2026) & (W Units) Table 47. Global Neuropeptide Y Receptor Type 2 Sales Market Share by Region (2021-2026) Table 48. Global Neuropeptide Y Receptor Type 2 Sales by Region (2027-2032) & (W Units) Table 49. Global Neuropeptide Y Receptor Type 2 Sales Market Share by Region (2027-2032) Table 50. Global Neuropeptide Y Receptor Type 2 Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 51. Global Neuropeptide Y Receptor Type 2 Sales Value by Region (2021-2026) & (US$ Million) Table 52. Global Neuropeptide Y Receptor Type 2 Sales Value Share by Region (2021-2026) Table 53. Global Neuropeptide Y Receptor Type 2 Sales Value by Region (2027-2032) & (US$ Million) Table 54. Global Neuropeptide Y Receptor Type 2 Sales Value Share by Region (2027-2032) Table 55. Global Neuropeptide Y Receptor Type 2 Market Average Price (US$/Unit) by Region (2021-2026) Table 56. Global Neuropeptide Y Receptor Type 2 Market Average Price (US$/Unit) by Region (2027-2032) Table 57. Global Neuropeptide Y Receptor Type 2 Sales by Country: 2021 VS 2025 VS 2032 (W Units) Table 58. Global Neuropeptide Y Receptor Type 2 Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 59. Global Neuropeptide Y Receptor Type 2 Sales by Country (2021-2026) & (W Units) Table 60. Global Neuropeptide Y Receptor Type 2 Sales Market Share by Country (2021-2026) Table 61. Global Neuropeptide Y Receptor Type 2 Sales by Country (2027-2032) & (W Units) Table 62. Global Neuropeptide Y Receptor Type 2 Sales Market Share by Country (2027-2032) Table 63. Global Neuropeptide Y Receptor Type 2 Sales Value by Country (2021-2026) & (US$ Million) Table 64. Global Neuropeptide Y Receptor Type 2 Sales Value Market Share by Country (2021-2026) Table 65. Global Neuropeptide Y Receptor Type 2 Sales Value by Country (2027-2032) & (US$ Million) Table 66. Global Neuropeptide Y Receptor Type 2 Sales Value Market Share by Country (2027-2032) Table 67. Novo Nordisk A/S Company Information Table 68. Novo Nordisk A/S Business Overview Table 69. Novo Nordisk A/S Neuropeptide Y Receptor Type 2 Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 70. Novo Nordisk A/S Neuropeptide Y Receptor Type 2 Product Portfolio Table 71. Novo Nordisk A/S Recent Development Table 72. XL-protein GmbH Company Information Table 73. XL-protein GmbH Business Overview Table 74. XL-protein GmbH Neuropeptide Y Receptor Type 2 Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 75. XL-protein GmbH Neuropeptide Y Receptor Type 2 Product Portfolio Table 76. XL-protein GmbH Recent Development Table 77. Gila Therapeutics Inc Company Information Table 78. Gila Therapeutics Inc Business Overview Table 79. Gila Therapeutics Inc Neuropeptide Y Receptor Type 2 Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 80. Gila Therapeutics Inc Neuropeptide Y Receptor Type 2 Product Portfolio Table 81. Gila Therapeutics Inc Recent Development Table 82. Key Raw Materials Table 83. Raw Materials Key Suppliers Table 84. Neuropeptide Y Receptor Type 2 Distributors List Table 85. Neuropeptide Y Receptor Type 2 Customers List Table 86. Research Programs/Design for This Report Table 87. Authors List of This Report Table 88. Secondary Sources Table 89. Primary Sources List of Figures Figure 1. Neuropeptide Y Receptor Type 2 Product Image Figure 2. Global Neuropeptide Y Receptor Type 2 Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Neuropeptide Y Receptor Type 2 Sales Value (2021-2032) & (US$ Million) Figure 4. Global Neuropeptide Y Receptor Type 2 Sales (2021-2032) & (W Units) Figure 5. Global Neuropeptide Y Receptor Type 2 Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Neuropeptide Y Receptor Type 2 Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. GT-002 Image Figure 10. NN-9748 Image Figure 11. XL-310 Image Figure 12. Others Image Figure 13. Global Neuropeptide Y Receptor Type 2 Sales Volume by Type (2021 VS 2025 VS 2032) & (W Units) Figure 14. Global Neuropeptide Y Receptor Type 2 Sales Volume Share 2021 VS 2025 VS 2032 Figure 15. Global Neuropeptide Y Receptor Type 2 Sales Volume Share by Type (2021-2032) Figure 16. Global Neuropeptide Y Receptor Type 2 Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Neuropeptide Y Receptor Type 2 Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global Neuropeptide Y Receptor Type 2 Sales Value Share by Type (2021-2032) Figure 19. Obesity Image Figure 20. Epilepsy Image Figure 21. Type 2 Diabetes Image Figure 22. Others Image Figure 23. Global Neuropeptide Y Receptor Type 2 Sales Volume by Application (2021 VS 2025 VS 2032) & (W Units) Figure 24. Global Neuropeptide Y Receptor Type 2 Sales Volume Share 2021 VS 2025 VS 2032 Figure 25. Global Neuropeptide Y Receptor Type 2 Sales Volume Share by Application (2021-2032) Figure 26. Global Neuropeptide Y Receptor Type 2 Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 27. Global Neuropeptide Y Receptor Type 2 Sales Value Share 2021 VS 2025 VS 2032 Figure 28. Global Neuropeptide Y Receptor Type 2 Sales Value Share by Application (2021-2032) Figure 29. Global Neuropeptide Y Receptor Type 2 Sales by Region: 2021 VS 2025 VS 2032 (W Units) Figure 30. Global Neuropeptide Y Receptor Type 2 Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 31. Global Neuropeptide Y Receptor Type 2 Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 32. Global Neuropeptide Y Receptor Type 2 Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 33. North America Neuropeptide Y Receptor Type 2 Sales Value (2021-2032) & (US$ Million) Figure 34. North America Neuropeptide Y Receptor Type 2 Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Europe Neuropeptide Y Receptor Type 2 Sales Value (2021-2032) & (US$ Million) Figure 36. Europe Neuropeptide Y Receptor Type 2 Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Asia-Pacific Neuropeptide Y Receptor Type 2 Sales Value (2021-2032) & (US$ Million) Figure 38. Asia-Pacific Neuropeptide Y Receptor Type 2 Sales Value Share by Country (%), 2025 VS 2032 Figure 39. South America Neuropeptide Y Receptor Type 2 Sales Value (2021-2032) & (US$ Million) Figure 40. South America Neuropeptide Y Receptor Type 2 Sales Value Share by Country (%), 2025 VS 2032 Figure 41. Middle East & Africa Neuropeptide Y Receptor Type 2 Sales Value (2021-2032) & (US$ Million) Figure 42. Middle East & Africa Neuropeptide Y Receptor Type 2 Sales Value Share by Country (%), 2025 VS 2032 Figure 43. USA Neuropeptide Y Receptor Type 2 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. USA Neuropeptide Y Receptor Type 2 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. USA Neuropeptide Y Receptor Type 2 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Canada Neuropeptide Y Receptor Type 2 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Canada Neuropeptide Y Receptor Type 2 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Canada Neuropeptide Y Receptor Type 2 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Mexico Neuropeptide Y Receptor Type 2 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Mexico Neuropeptide Y Receptor Type 2 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Mexico Neuropeptide Y Receptor Type 2 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Germany Neuropeptide Y Receptor Type 2 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Germany Neuropeptide Y Receptor Type 2 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Germany Neuropeptide Y Receptor Type 2 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. France Neuropeptide Y Receptor Type 2 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. France Neuropeptide Y Receptor Type 2 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. France Neuropeptide Y Receptor Type 2 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. U.K. Neuropeptide Y Receptor Type 2 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. U.K. Neuropeptide Y Receptor Type 2 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. U.K. Neuropeptide Y Receptor Type 2 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Italy Neuropeptide Y Receptor Type 2 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Italy Neuropeptide Y Receptor Type 2 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Italy Neuropeptide Y Receptor Type 2 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Spain Neuropeptide Y Receptor Type 2 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Spain Neuropeptide Y Receptor Type 2 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Spain Neuropeptide Y Receptor Type 2 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Russia Neuropeptide Y Receptor Type 2 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Russia Neuropeptide Y Receptor Type 2 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Russia Neuropeptide Y Receptor Type 2 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Netherlands Neuropeptide Y Receptor Type 2 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Netherlands Neuropeptide Y Receptor Type 2 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Netherlands Neuropeptide Y Receptor Type 2 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. Nordic Countries Neuropeptide Y Receptor Type 2 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. Nordic Countries Neuropeptide Y Receptor Type 2 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. Nordic Countries Neuropeptide Y Receptor Type 2 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. China Neuropeptide Y Receptor Type 2 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. China Neuropeptide Y Receptor Type 2 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. China Neuropeptide Y Receptor Type 2 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Japan Neuropeptide Y Receptor Type 2 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Japan Neuropeptide Y Receptor Type 2 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Japan Neuropeptide Y Receptor Type 2 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. South Korea Neuropeptide Y Receptor Type 2 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. South Korea Neuropeptide Y Receptor Type 2 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. South Korea Neuropeptide Y Receptor Type 2 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. India Neuropeptide Y Receptor Type 2 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. India Neuropeptide Y Receptor Type 2 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. India Neuropeptide Y Receptor Type 2 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Australia Neuropeptide Y Receptor Type 2 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Australia Neuropeptide Y Receptor Type 2 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Australia Neuropeptide Y Receptor Type 2 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Southeast Asia Neuropeptide Y Receptor Type 2 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Southeast Asia Neuropeptide Y Receptor Type 2 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Southeast Asia Neuropeptide Y Receptor Type 2 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Brazil Neuropeptide Y Receptor Type 2 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Brazil Neuropeptide Y Receptor Type 2 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Brazil Neuropeptide Y Receptor Type 2 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Argentina Neuropeptide Y Receptor Type 2 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Argentina Neuropeptide Y Receptor Type 2 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Argentina Neuropeptide Y Receptor Type 2 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Chile Neuropeptide Y Receptor Type 2 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Chile Neuropeptide Y Receptor Type 2 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Chile Neuropeptide Y Receptor Type 2 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Colombia Neuropeptide Y Receptor Type 2 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Colombia Neuropeptide Y Receptor Type 2 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Colombia Neuropeptide Y Receptor Type 2 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Peru Neuropeptide Y Receptor Type 2 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Peru Neuropeptide Y Receptor Type 2 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Peru Neuropeptide Y Receptor Type 2 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Saudi Arabia Neuropeptide Y Receptor Type 2 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Saudi Arabia Neuropeptide Y Receptor Type 2 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Saudi Arabia Neuropeptide Y Receptor Type 2 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Israel Neuropeptide Y Receptor Type 2 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Israel Arabia Neuropeptide Y Receptor Type 2 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Israel Arabia Neuropeptide Y Receptor Type 2 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. UAE Neuropeptide Y Receptor Type 2 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. UAE Neuropeptide Y Receptor Type 2 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. UAE Neuropeptide Y Receptor Type 2 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Turkey Neuropeptide Y Receptor Type 2 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Turkey Neuropeptide Y Receptor Type 2 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Turkey Neuropeptide Y Receptor Type 2 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Iran Neuropeptide Y Receptor Type 2 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Iran Neuropeptide Y Receptor Type 2 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Iran Neuropeptide Y Receptor Type 2 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Egypt Neuropeptide Y Receptor Type 2 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 125. Egypt Neuropeptide Y Receptor Type 2 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 126. Egypt Neuropeptide Y Receptor Type 2 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 127. Neuropeptide Y Receptor Type 2 Value Chain Figure 128. Manufacturing Cost Structure Figure 129. Neuropeptide Y Receptor Type 2 Sales Mode & Process Figure 130. Direct Comparison with Distribution Share Figure 131. Distributors Profiles Figure 132. Years Considered Figure 133. Research Process Figure 134. Key Executives Interviewed

Scope & coverage.

Types
  • GT-002
  • NN-9748
  • XL-310
  • Others
Applications
  • Obesity
  • Epilepsy
  • Type 2 Diabetes
  • Others
Companies covered
  • Novo Nordisk A/S
  • XL-protein GmbH
  • Gila Therapeutics Inc

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Neuropeptide Y Receptor Type 2 Sales Value (2021-2032)
  4. 1.2.2 Global Neuropeptide Y Receptor Type 2 Sales Volume (2021-2032)
  5. 1.2.3 Global Neuropeptide Y Receptor Type 2 Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Neuropeptide Y Receptor Type 2 Market Dynamics
  1. 2.1 Neuropeptide Y Receptor Type 2 Industry Trends
  2. 2.2 Neuropeptide Y Receptor Type 2 Industry Drivers
  3. 2.3 Neuropeptide Y Receptor Type 2 Industry Opportunities and Challenges
  4. 2.4 Neuropeptide Y Receptor Type 2 Industry Restraints
3 Neuropeptide Y Receptor Type 2 Market by Company
  1. 3.1 Global Neuropeptide Y Receptor Type 2 Company Revenue Ranking in 2025
  2. 3.2 Global Neuropeptide Y Receptor Type 2 Revenue by Company (2021-2026)
  3. 3.3 Global Neuropeptide Y Receptor Type 2 Sales Volume by Company (2021-2026)
  4. 3.4 Global Neuropeptide Y Receptor Type 2 Average Price by Company (2021-2026)
  5. 3.5 Global Neuropeptide Y Receptor Type 2 Company Ranking (2024-2026)
  6. 3.6 Global Neuropeptide Y Receptor Type 2 Company Manufacturing Base and Headquarters
  7. 3.7 Global Neuropeptide Y Receptor Type 2 Company Product Type and Application
  8. 3.8 Global Neuropeptide Y Receptor Type 2 Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Neuropeptide Y Receptor Type 2 Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Neuropeptide Y Receptor Type 2 Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Neuropeptide Y Receptor Type 2 Market by Type
  1. 4.1 Neuropeptide Y Receptor Type 2 Type Introduction
  2. 4.1.1 GT-002
  3. 4.1.2 NN-9748
  4. 4.1.3 XL-310
  5. 4.1.4 Others
  6. 4.2 Global Neuropeptide Y Receptor Type 2 Sales Volume by Type
  7. 4.2.1 Global Neuropeptide Y Receptor Type 2 Sales Volume by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Neuropeptide Y Receptor Type 2 Sales Volume by Type (2021-2032)
  9. 4.2.3 Global Neuropeptide Y Receptor Type 2 Sales Volume Share by Type (2021-2032)
  10. 4.3 Global Neuropeptide Y Receptor Type 2 Sales Value by Type
  11. 4.3.1 Global Neuropeptide Y Receptor Type 2 Sales Value by Type (2021 VS 2025 VS 2032)
  12. 4.3.2 Global Neuropeptide Y Receptor Type 2 Sales Value by Type (2021-2032)
  13. 4.3.3 Global Neuropeptide Y Receptor Type 2 Sales Value Share by Type (2021-2032)
5 Neuropeptide Y Receptor Type 2 Market by Application
  1. 5.1 Neuropeptide Y Receptor Type 2 Application Introduction
  2. 5.1.1 Obesity
  3. 5.1.2 Epilepsy
  4. 5.1.3 Type 2 Diabetes
  5. 5.1.4 Others
  6. 5.2 Global Neuropeptide Y Receptor Type 2 Sales Volume by Application
  7. 5.2.1 Global Neuropeptide Y Receptor Type 2 Sales Volume by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Neuropeptide Y Receptor Type 2 Sales Volume by Application (2021-2032)
  9. 5.2.3 Global Neuropeptide Y Receptor Type 2 Sales Volume Share by Application (2021-2032)
  10. 5.3 Global Neuropeptide Y Receptor Type 2 Sales Value by Application
  11. 5.3.1 Global Neuropeptide Y Receptor Type 2 Sales Value by Application (2021 VS 2025 VS 2032)
  12. 5.3.2 Global Neuropeptide Y Receptor Type 2 Sales Value by Application (2021-2032)
  13. 5.3.3 Global Neuropeptide Y Receptor Type 2 Sales Value Share by Application (2021-2032)
6 Neuropeptide Y Receptor Type 2 Regional Sales and Value Analysis
  1. 6.1 Global Neuropeptide Y Receptor Type 2 Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Neuropeptide Y Receptor Type 2 Sales by Region (2021-2032)
  3. 6.2.1 Global Neuropeptide Y Receptor Type 2 Sales by Region: 2021-2026
  4. 6.2.2 Global Neuropeptide Y Receptor Type 2 Sales by Region (2027-2032)
  5. 6.3 Global Neuropeptide Y Receptor Type 2 Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Neuropeptide Y Receptor Type 2 Sales Value by Region (2021-2032)
  7. 6.4.1 Global Neuropeptide Y Receptor Type 2 Sales Value by Region: 2021-2026
  8. 6.4.2 Global Neuropeptide Y Receptor Type 2 Sales Value by Region (2027-2032)
  9. 6.5 Global Neuropeptide Y Receptor Type 2 Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Neuropeptide Y Receptor Type 2 Sales Value (2021-2032)
  12. 6.6.2 North America Neuropeptide Y Receptor Type 2 Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Neuropeptide Y Receptor Type 2 Sales Value (2021-2032)
  15. 6.7.2 Europe Neuropeptide Y Receptor Type 2 Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Neuropeptide Y Receptor Type 2 Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Neuropeptide Y Receptor Type 2 Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Neuropeptide Y Receptor Type 2 Sales Value (2021-2032)
  21. 6.9.2 South America Neuropeptide Y Receptor Type 2 Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Neuropeptide Y Receptor Type 2 Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Neuropeptide Y Receptor Type 2 Sales Value Share by Country, 2025 VS 2032
7 Neuropeptide Y Receptor Type 2 Country-level Sales and Value Analysis
  1. 7.1 Global Neuropeptide Y Receptor Type 2 Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Neuropeptide Y Receptor Type 2 Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Neuropeptide Y Receptor Type 2 Sales by Country (2021-2032)
  4. 7.3.1 Global Neuropeptide Y Receptor Type 2 Sales by Country (2021-2026)
  5. 7.3.2 Global Neuropeptide Y Receptor Type 2 Sales by Country (2027-2032)
  6. 7.4 Global Neuropeptide Y Receptor Type 2 Sales Value by Country (2021-2032)
  7. 7.4.1 Global Neuropeptide Y Receptor Type 2 Sales Value by Country (2021-2026)
  8. 7.4.2 Global Neuropeptide Y Receptor Type 2 Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Neuropeptide Y Receptor Type 2 Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Neuropeptide Y Receptor Type 2 Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Neuropeptide Y Receptor Type 2 Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Neuropeptide Y Receptor Type 2 Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Neuropeptide Y Receptor Type 2 Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Neuropeptide Y Receptor Type 2 Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Neuropeptide Y Receptor Type 2 Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Neuropeptide Y Receptor Type 2 Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Neuropeptide Y Receptor Type 2 Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Neuropeptide Y Receptor Type 2 Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Neuropeptide Y Receptor Type 2 Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Neuropeptide Y Receptor Type 2 Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Neuropeptide Y Receptor Type 2 Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Neuropeptide Y Receptor Type 2 Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Neuropeptide Y Receptor Type 2 Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Neuropeptide Y Receptor Type 2 Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Neuropeptide Y Receptor Type 2 Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Neuropeptide Y Receptor Type 2 Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Neuropeptide Y Receptor Type 2 Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Neuropeptide Y Receptor Type 2 Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Neuropeptide Y Receptor Type 2 Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Neuropeptide Y Receptor Type 2 Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Neuropeptide Y Receptor Type 2 Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Neuropeptide Y Receptor Type 2 Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Neuropeptide Y Receptor Type 2 Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Neuropeptide Y Receptor Type 2 Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Neuropeptide Y Receptor Type 2 Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Neuropeptide Y Receptor Type 2 Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Neuropeptide Y Receptor Type 2 Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Neuropeptide Y Receptor Type 2 Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Neuropeptide Y Receptor Type 2 Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Neuropeptide Y Receptor Type 2 Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Neuropeptide Y Receptor Type 2 Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Neuropeptide Y Receptor Type 2 Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Neuropeptide Y Receptor Type 2 Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Neuropeptide Y Receptor Type 2 Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Neuropeptide Y Receptor Type 2 Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Neuropeptide Y Receptor Type 2 Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Neuropeptide Y Receptor Type 2 Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Neuropeptide Y Receptor Type 2 Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Neuropeptide Y Receptor Type 2 Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Neuropeptide Y Receptor Type 2 Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Neuropeptide Y Receptor Type 2 Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Neuropeptide Y Receptor Type 2 Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Neuropeptide Y Receptor Type 2 Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Neuropeptide Y Receptor Type 2 Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Neuropeptide Y Receptor Type 2 Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Neuropeptide Y Receptor Type 2 Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Neuropeptide Y Receptor Type 2 Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Neuropeptide Y Receptor Type 2 Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Neuropeptide Y Receptor Type 2 Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Neuropeptide Y Receptor Type 2 Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Neuropeptide Y Receptor Type 2 Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Neuropeptide Y Receptor Type 2 Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Neuropeptide Y Receptor Type 2 Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Neuropeptide Y Receptor Type 2 Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Neuropeptide Y Receptor Type 2 Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Neuropeptide Y Receptor Type 2 Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Neuropeptide Y Receptor Type 2 Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Neuropeptide Y Receptor Type 2 Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Neuropeptide Y Receptor Type 2 Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Neuropeptide Y Receptor Type 2 Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Neuropeptide Y Receptor Type 2 Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Neuropeptide Y Receptor Type 2 Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Neuropeptide Y Receptor Type 2 Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Neuropeptide Y Receptor Type 2 Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Neuropeptide Y Receptor Type 2 Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Neuropeptide Y Receptor Type 2 Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Neuropeptide Y Receptor Type 2 Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Neuropeptide Y Receptor Type 2 Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Neuropeptide Y Receptor Type 2 Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Neuropeptide Y Receptor Type 2 Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Neuropeptide Y Receptor Type 2 Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Neuropeptide Y Receptor Type 2 Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Neuropeptide Y Receptor Type 2 Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Neuropeptide Y Receptor Type 2 Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Neuropeptide Y Receptor Type 2 Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Neuropeptide Y Receptor Type 2 Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Neuropeptide Y Receptor Type 2 Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Neuropeptide Y Receptor Type 2 Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Neuropeptide Y Receptor Type 2 Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Neuropeptide Y Receptor Type 2 Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Neuropeptide Y Receptor Type 2 Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Neuropeptide Y Receptor Type 2 Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Novo Nordisk A/S
  2. 8.1.1 Novo Nordisk A/S Company Information
  3. 8.1.2 Novo Nordisk A/S Business Overview
  4. 8.1.3 Novo Nordisk A/S Neuropeptide Y Receptor Type 2 Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Novo Nordisk A/S Neuropeptide Y Receptor Type 2 Product Portfolio
  6. 8.1.5 Novo Nordisk A/S Recent Developments
  7. 8.2 XL-protein GmbH
  8. 8.2.1 XL-protein GmbH Company Information
  9. 8.2.2 XL-protein GmbH Business Overview
  10. 8.2.3 XL-protein GmbH Neuropeptide Y Receptor Type 2 Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 XL-protein GmbH Neuropeptide Y Receptor Type 2 Product Portfolio
  12. 8.2.5 XL-protein GmbH Recent Developments
  13. 8.3 Gila Therapeutics Inc
  14. 8.3.1 Gila Therapeutics Inc Company Information
  15. 8.3.2 Gila Therapeutics Inc Business Overview
  16. 8.3.3 Gila Therapeutics Inc Neuropeptide Y Receptor Type 2 Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Gila Therapeutics Inc Neuropeptide Y Receptor Type 2 Product Portfolio
  18. 8.3.5 Gila Therapeutics Inc Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Neuropeptide Y Receptor Type 2 Value Chain Analysis
  2. 9.1.1 Neuropeptide Y Receptor Type 2 Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Neuropeptide Y Receptor Type 2 Sales Mode & Process
  6. 9.2 Neuropeptide Y Receptor Type 2 Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Neuropeptide Y Receptor Type 2 Distributors
  9. 9.2.3 Neuropeptide Y Receptor Type 2 Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst